fashion -WSS

fashion

author：entertainment 2025-10-01 18:23:22 - browse：65

An ALS patient receives support. -- health coverage from STAT — Adobe

Years of polarizing scientific discourse and bruising online debate will come to a head next week when advisers to the Food and Drug Administration weigh in on NurOwn, a potential treatment to slow the progression of ALS that has bitterly divided physicians and patient advocates.

On Sept. 27, a panel of experts will consider the convoluted data supporting the potential approval of NurOwn, a stem-cell therapy the FDA previously refused to even consider. To some physicians, the drug’s failure to show significant benefits in clinical studies leaves approval out of the question. Others, including the influential ALS Association, say NurOwn’s manufacturer, a small biotech firm called BrainStorm Cell Therapeutics, hasn’t disclosed enough information to properly determine the medicine’s value.

Another group of patients and doctors argue that NurOwn’s supporting evidence, while problematic, justifies making it available to the roughly 30,000 ALS patients in the U.S., people for whom there is currently no hope of arresting an incurable disease that gradually erodes motor function and leads to death within about five years of diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Readout LOUD podcast: The Sarepta saga, decoding biotech hype

hotspot

leisure time

hotspot

WSS

CMS got Medicare Advantage quality rating wrong, judge rules

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Gene therapy’s promise and the high cost of hope

Gene therapy’s promise and the high cost of hope

Sarepta Duchenne therapy fails to meet primary endpoint in trial

hotspot

fashion

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How to convince healthy people to buy insurance

Supreme Court strikes down use of affirmative action

Medicare Advantage's lean provider networks lead CMS complaints

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Sutter Health’s antitrust win overturned by appeals court

Duchenne breakthrough therapy leaves behind pioneering families

What is microchimerism and how does it affect maternal health?

Anesthesiologist group: stop taking Ozempic before surgery

The health care issue Democrats can’t solve: hospital reform

focus

Lung cancer screening guidelines updated for cigarette smokers

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

CMS got Medicare Advantage quality rating wrong, judge rules

What is microchimerism and how does it affect maternal health?

The health care issue Democrats can’t solve: hospital reform

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

hotspot

leisure time

hotspot

entertainment